These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26935940)

  • 1. Emerging targets and new small molecule therapies in Parkinson's disease treatment.
    Zhang H; Tong R; Bai L; Shi J; Ouyang L
    Bioorg Med Chem; 2016 Apr; 24(7):1419-30. PubMed ID: 26935940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in discovery and development of natural products as source for anti-Parkinson's disease lead compounds.
    Zhang H; Bai L; He J; Zhong L; Duan X; Ouyang L; Zhu Y; Wang T; Zhang Y; Shi J
    Eur J Med Chem; 2017 Dec; 141():257-272. PubMed ID: 29031072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.
    Ivanenkov YA; Veselov MS; Chufarova NV; Majouga AG; Kudryavceva AA; Ivachtchenko AV
    Mol Divers; 2016 Feb; 20(1):345-65. PubMed ID: 25956815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Return of D
    Lindsley CW; Hopkins CR
    J Med Chem; 2017 Sep; 60(17):7233-7243. PubMed ID: 28489950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.
    Zhong Z; He X; Ge J; Zhu J; Yao C; Cai H; Ye XY; Xie T; Bai R
    Eur J Med Chem; 2022 Jul; 237():114378. PubMed ID: 35462165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of estrogens in Parkinson's disease].
    Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Fragment-Based Method of Creating Small-Molecule Libraries to Target the Aggregation of Intrinsically Disordered Proteins.
    Joshi P; Chia S; Habchi J; Knowles TP; Dobson CM; Vendruscolo M
    ACS Comb Sci; 2016 Mar; 18(3):144-53. PubMed ID: 26923286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in drug development for Parkinson's disease: present status.
    Harikrishna Reddy D; Misra S; Medhi B
    Pharmacology; 2014; 93(5-6):260-71. PubMed ID: 25096413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New small molecules for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1077-86. PubMed ID: 20645881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational drug discovery design approaches for treating Parkinson's disease.
    Van der Schyf CJ
    Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease.
    Fumagalli F; Racagni G; Riva MA
    Pharmacogenomics J; 2006; 6(2):95-104. PubMed ID: 16402079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions.
    Johnson ME; Bobrovskaya L
    Neurotoxicology; 2015 Jan; 46():101-16. PubMed ID: 25514659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
    Rojas RJ; Edmondson DE; Almos T; Scott R; Massari ME
    Bioorg Med Chem; 2015 Feb; 23(4):770-8. PubMed ID: 25600407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurotrophic factors for the treatment of Parkinson's disease.
    Chiocco MJ; Harvey BK; Wang Y; Hoffer BJ
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S321-8. PubMed ID: 18267258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
    Tsai SJ
    Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management of Parkinson's disease.
    Salawu F; Olokoba A; Danburam A
    Ann Afr Med; 2010; 9(2):55-61. PubMed ID: 20587924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.